Back to Journals » Drug Design, Development and Therapy » Volume 11

Paeoniflorin suppresses pancreatic cancer cell growth by upregulating HTRA3 expression

Authors Li YJ, Gong LL, Qi RL, Sun Q, Xia XX, He HH, Ren JS, Zhu ON, Zhuo DB

Received 19 April 2017

Accepted for publication 29 June 2017

Published 23 August 2017 Volume 2017:11 Pages 2481—2491


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Anastasios Lymperopoulos

Yuejun Li,1,* Lili Gong,2,* Ruili Qi,2 Qian Sun,2 Xinxin Xia,3 Haihui He,1 Jianshu Ren,1 Ouning Zhu,1 Debin Zhuo1

1The Third Department of Oncology, The First Affiliated Hospital of Hunan College of Traditional Chinese Medicine, Zhuzhou, Hunan, 2State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, 3Department of Traditional Chinese Medicine, The First Affiliated Hospital of Xian Jiaotong University, Xian, Shanxi, People’s Republic of China

*These authors contributed equally to this work

Abstract: Paeoniflorin (PF) is an active monoterpene glycoside extracted from Paeonia lactiflora Pall. PF has exhibited antitumor effects in various cancer types. However, the effects of PF in pancreatic cancer are largely unexplored. Here, we showed that PF suppressed growth of pancreatic cancer cell lines Capan-1 and MIAPaCa-2 and profoundly sensitized these cells to X-ray irradiation. Through microarray analysis, we identified HTRA3, a tumor-suppressor candidate gene, as the most increased gene upon PF treatment in Capan-1 cells. Ectopic expression of HTRA3 led to reduced cell proliferation and increased expression of apoptotic protein Bax, suggesting a tumor suppressive role of HTRA3 in pancreatic cancer cells. Together, our results provide a set group of genetic proofs and biological proofs that PF inhibited pancreatic cancer growth by upregulating HTRA3.

Keywords: traditional Chinese medicine, X-ray irradiation, colony formation assay, microarray analysis, cancer inhibition

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]